Vaccine Strategy For Trichomonas?

29 September 1996

Research conducted at the University of Ottawa in Canada has resulted in a vaccine strategy which holds promise for the treatment of trichomoniasis, the most common sexually-transmitted disease worldwide. Although not intrinsically serious, the disease can increase HIV transmission in women, and is also associated with an increased incidence of pregnancy loss. The strategy, tested in a mouse model, involves the subcutaneous administration of Trichomonas vaginalis, the causative protozoan, in two doses given a month apart. Vaccination prevented or hastened the eradication of subsequent vaginal challenge with T vaginalis.

- Meantime, another study has suggested that the combination of estrogen and progesterone in the low-dose contraceptive pill can help prevent trichomoniasis. It appears that the presence of estrogen receptors on the organism plays an important role in preventing T vaginalis infection in women on combination oral contraceptives, according to researchers from the University of Minnesota, USA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight